Rhino-Conjunctivitis-Pipeline Review, H1 2016

Rhino-Conjunctivitis-Pipeline Review, H1 2016

  • Products Id :- GMDHC8178IDB
  • |
  • Pages: 90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rhino-Conjunctivitis-Pipeline Review, H1 2016


Global Markets Direct's, 'Rhino-Conjunctivitis-Pipeline Review, H1 2016', provides an overview of the Rhino-Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis

The report reviews pipeline therapeutics for Rhino-Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rhino-Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Rhino-Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rhino-Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Rhino-Conjunctivitis Overview 9

Therapeutics Development 10

Pipeline Products for Rhino-Conjunctivitis-Overview 10

Rhino-Conjunctivitis-Therapeutics under Development by Companies 11

Rhino-Conjunctivitis-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Rhino-Conjunctivitis-Products under Development by Companies 15

Rhino-Conjunctivitis-Companies Involved in Therapeutics Development 17

ALK-Abello A/S 17

Allergy Therapeutics Plc 18

ASIT biotech s.a. 19

Bial-Portela & Ca, S.A. 20

Circassia Pharmaceuticals Plc 21

Faes Farma, S.A. 22

Griffin Discoveries BV 23

HAL Allergy BV 24

Immunomic Therapeutics, Inc. 25

Laboratorios LETI S.L. 26

Oxagen Limited 27

Roxall Medizin GmbH 28

Stallergenes SAS 29

Rhino-Conjunctivitis-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Allergen for Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Allergen for Allergic Rhino-Conjunctivitis-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Allergovac-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ASP-4070-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

bilastine-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

clustoid wiesenlieschgras-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

gp-ASIT-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

OC-000459-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

OC-2417-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Pollinex Quattro Grass-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Rhino-Conjunctivitis-Dormant Projects 80

Rhino-Conjunctivitis-Discontinued Products 81

Rhino-Conjunctivitis-Product Development Milestones 82

Featured News & Press Releases 82

Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study 82

Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 83

May 18, 2014: BioTech Tools will be present at the EAACI congress 84

Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 85

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 86

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 87

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 87

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study 88

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Assessment by Monotherapy Products, H1 2016 30

Number of Products by Targets, H1 2016 32

Number of Products by Stage and Targets, H1 2016 32

Number of Products by Mechanism of Actions, H1 2016 34

Number of Products by Stage and Mechanism of Actions, H1 2016 34

Number of Products by Routes of Administration, H1 2016 36

Number of Products by Stage and Routes of Administration, H1 2016 36

Number of Products by Molecule Types, H1 2016 38

Number of Products by Stage and Molecule Types, H1 2016 38

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 (Contd..1) 16

Rhino-Conjunctivitis-Pipeline by ALK-Abello A/S, H1 2016 17

Rhino-Conjunctivitis-Pipeline by Allergy Therapeutics Plc, H1 2016 18

Rhino-Conjunctivitis-Pipeline by ASIT biotech s.a., H1 2016 19

Rhino-Conjunctivitis-Pipeline by Bial-Portela & Ca, S.A., H1 2016 20

Rhino-Conjunctivitis-Pipeline by Circassia Pharmaceuticals Plc, H1 2016 21

Rhino-Conjunctivitis-Pipeline by Faes Farma, S.A., H1 2016 22

Rhino-Conjunctivitis-Pipeline by Griffin Discoveries BV, H1 2016 23

Rhino-Conjunctivitis-Pipeline by HAL Allergy BV, H1 2016 24

Rhino-Conjunctivitis-Pipeline by Immunomic Therapeutics, Inc., H1 2016 25

Rhino-Conjunctivitis-Pipeline by Laboratorios LETI S.L., H1 2016 26

Rhino-Conjunctivitis-Pipeline by Oxagen Limited, H1 2016 27

Rhino-Conjunctivitis-Pipeline by Roxall Medizin GmbH, H1 2016 28

Rhino-Conjunctivitis-Pipeline by Stallergenes SAS, H1 2016 29

Assessment by Monotherapy Products, H1 2016 30

Assessment by Combination Products, H1 2016 31

Number of Products by Stage and Target, H1 2016 33

Number of Products by Stage and Mechanism of Action, H1 2016 35

Number of Products by Stage and Route of Administration, H1 2016 37

Number of Products by Stage and Molecule Type, H1 2016 39

Rhino-Conjunctivitis-Dormant Projects, H1 2016 80

Rhino-Conjunctivitis-Discontinued Products, H1 2016 81

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

ALK-Abello A/S

Allergy Therapeutics Plc

ASIT biotech s.a.

Bial-Portela & Ca, S.A.

Circassia Pharmaceuticals Plc

Faes Farma, S.A.

Griffin Discoveries BV

HAL Allergy BV

Immunomic Therapeutics, Inc.

Laboratorios LETI S.L.

Oxagen Limited

Roxall Medizin GmbH

Stallergenes SAS

Rhino-Conjunctivitis Therapeutic Products under Development, Key Players in Rhino-Conjunctivitis Therapeutics, Rhino-Conjunctivitis Pipeline Overview, Rhino-Conjunctivitis Pipeline, Rhino-Conjunctivitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 147300
Site License
USD 4000 INR 294600
Corporate User License
USD 6000 INR 441900



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com